Advanced Asset Management Advisors Inc Sells 294 Shares of Eli Lilly and Company (NYSE:LLY)

Advanced Asset Management Advisors Inc reduced its stake in shares of Eli Lilly and Company (NYSE:LLY) by 42.3% in the 4th quarter, HoldingsChannel.com reports. The fund owned 401 shares of the company’s stock after selling 294 shares during the quarter. Advanced Asset Management Advisors Inc’s holdings in Eli Lilly and Company were worth $234,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in LLY. JGP Wealth Management LLC increased its holdings in shares of Eli Lilly and Company by 0.9% during the fourth quarter. JGP Wealth Management LLC now owns 1,843 shares of the company’s stock worth $1,074,000 after buying an additional 16 shares in the last quarter. Walkner Condon Financial Advisors LLC boosted its stake in Eli Lilly and Company by 2.8% in the third quarter. Walkner Condon Financial Advisors LLC now owns 621 shares of the company’s stock worth $334,000 after purchasing an additional 17 shares in the last quarter. Patton Albertson Miller Group LLC increased its stake in shares of Eli Lilly and Company by 2.8% in the third quarter. Patton Albertson Miller Group LLC now owns 623 shares of the company’s stock valued at $335,000 after buying an additional 17 shares in the last quarter. Valley Wealth Managers Inc. lifted its position in Eli Lilly and Company by 1.3% during the 3rd quarter. Valley Wealth Managers Inc. now owns 1,280 shares of the company’s stock worth $688,000 after buying an additional 17 shares in the last quarter. Finally, Sandy Cove Advisors LLC grew its holdings in Eli Lilly and Company by 0.8% during the 4th quarter. Sandy Cove Advisors LLC now owns 2,241 shares of the company’s stock worth $1,307,000 after acquiring an additional 17 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the stock. Citigroup upped their target price on shares of Eli Lilly and Company from $675.00 to $895.00 and gave the stock a “buy” rating in a research report on Tuesday, April 2nd. Wells Fargo & Company raised their price target on Eli Lilly and Company from $700.00 to $825.00 and gave the company an “overweight” rating in a report on Tuesday, February 6th. The Goldman Sachs Group boosted their price objective on Eli Lilly and Company from $650.00 to $723.00 and gave the stock a “neutral” rating in a report on Thursday, April 11th. DZ Bank cut shares of Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 price target for the company. in a research report on Wednesday, February 21st. Finally, Barclays increased their price objective on shares of Eli Lilly and Company from $680.00 to $810.00 and gave the company an “overweight” rating in a report on Wednesday, February 7th. Three investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $728.05.

Insider Buying and Selling at Eli Lilly and Company

In other news, major shareholder Lilly Endowment Inc sold 78,573 shares of the stock in a transaction that occurred on Wednesday, January 31st. The stock was sold at an average price of $648.07, for a total transaction of $50,920,804.11. Following the transaction, the insider now owns 99,333,810 shares in the company, valued at $64,375,262,246.70. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 0.13% of the company’s stock.

Eli Lilly and Company Stock Performance

LLY traded down $7.33 during trading hours on Thursday, reaching $724.87. The company’s stock had a trading volume of 2,597,583 shares, compared to its average volume of 3,034,002. The company’s 50-day moving average is $763.40 and its 200-day moving average is $664.52. Eli Lilly and Company has a 52 week low of $370.68 and a 52 week high of $800.78. The firm has a market cap of $688.74 billion, a PE ratio of 124.61, a price-to-earnings-growth ratio of 1.63 and a beta of 0.34. The company has a debt-to-equity ratio of 1.69, a quick ratio of 0.73 and a current ratio of 0.94.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Tuesday, February 6th. The company reported $2.49 EPS for the quarter, beating the consensus estimate of $2.30 by $0.19. The firm had revenue of $9.35 billion for the quarter, compared to the consensus estimate of $8.95 billion. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The company’s quarterly revenue was up 28.1% on a year-over-year basis. During the same period in the previous year, the company earned $2.09 earnings per share. On average, equities analysts forecast that Eli Lilly and Company will post 12.52 EPS for the current year.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.